GRI Bio, Inc. (GRI), a biotechnology company, Wednesday announced preclinical data showing that its lead drug candidate GRI-0621 has both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis.
The data were presented at the 2025 ATS International Conference.
GRI-0621 is currently being evaluated in a Phase 2a study in patients with Idiopathic Pulmonary Fibrosis (IPF). Topline results from the study are expected in the third quarter of 2025.
Results from 6-week interim analysis in ongoing Phase 2a study of
GRI-0621 are anticipated in the second quarter of 2025.
For comments and feedback: editorial@rttnews.com